These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1627393)

  • 1. New approaches in cancer pharmacology: drug design and development. Report of a European School of Oncology Task Force.
    Eur J Cancer; 1992; 28A(6-7):1190-200. PubMed ID: 1627393
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging approaches in molecular profiling affecting oncology drug discovery.
    Friend SH
    Cold Spring Harb Symp Quant Biol; 2005; 70():445-8. PubMed ID: 16869782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 4. [Oncogenes and pharmacological approaches to cancer therapy].
    Tocque B
    Pathol Biol (Paris); 1992 Nov; 39(9):869-70. PubMed ID: 1538914
    [No Abstract]   [Full Text] [Related]  

  • 5. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
    Petty RD
    Clin Oncol (R Coll Radiol); 1996; 8(3):186-9. PubMed ID: 8814375
    [No Abstract]   [Full Text] [Related]  

  • 6. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2).
    Workman P; D'Incalci M; Bursch W; Harrap KR; Hawkins RE; Neidle S; Powis G
    Eur J Cancer; 1994; 30A(8):1148-60. PubMed ID: 7654448
    [No Abstract]   [Full Text] [Related]  

  • 8. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern molecular approaches to drug design and discovery.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):2-3. PubMed ID: 18193819
    [No Abstract]   [Full Text] [Related]  

  • 10. New drugs and novel agents.
    Workman P
    Curr Opin Oncol; 1989 Dec; 1(2):213-21. PubMed ID: 2489963
    [No Abstract]   [Full Text] [Related]  

  • 11. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
    Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ether lipids in the therapy of cancer.
    Andreesen R
    Prog Biochem Pharmacol; 1988; 22():118-31. PubMed ID: 3043427
    [No Abstract]   [Full Text] [Related]  

  • 13. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
    Smith PJ
    Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Problems in the design of anticancer agents.
    D'Incalci M; Balconi G; Broggini M; Colombo T; Marzola M; Morali F; Pang Y; Sen S; Spinelli L
    Cancer Surv; 1989; 8(3):535-55. PubMed ID: 2701084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing new agents for the treatment of childhood cancer.
    Kurmasheva R; Morton C; Houghton PJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 19. Signalling targets for the development of cancer drugs.
    Powis G; Workman P
    Anticancer Drug Des; 1994 Dec; 9(6):555-68. PubMed ID: 7880380
    [No Abstract]   [Full Text] [Related]  

  • 20. Signalling targets for the development of cancer drugs.
    Powis G; Workman P
    Anticancer Drug Des; 1994 Aug; 9(4):263-77. PubMed ID: 7916896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.